

Lumito strengthens its commercial position through partnership with Aurevia in advanced tissue analysis

Lumito AB (publ) ("Lumito" or the "Company") has entered into a collaboration with Aurevia AB ("Aurevia"), a CRO company specialising in clinical research and regulatory services. Through the collaboration, Lumito gains access to an additional established channel for reaching potential customers in drug development and clinical research. At the same time, Aurevia can broaden its offering with Lumito's highly sensitive SCIZYS® technology for advanced tissue analysis. The collaboration strengthens both companies' offerings, increases customer value and creates opportunities for new commercial business.

Within cancer research and drug development, there is a growing need for analytical methods that can identify and measure biomarkers with high precision. Such methods can contribute to an increased understanding of disease mechanisms and the development of new pharmaceuticals and future diagnostic methods.

Lumito's patented SCIZYS technology enables the detection of specific proteins in tissue samples with very high sensitivity and minimal background interference and has been developed to address this type of analytical challenge. By combining high detection sensitivity with quantitative analysis, the technology can provide researchers with more detailed information about biological markers than is possible with many conventional analytical methods.

For Lumito, the partnership with Aurevia represents another step in the work to strengthen the Company's commercial presence and introduce SCIZYS to more stakeholders within research and development. Through Aurevia's established customer relationships and experience in clinical research, new opportunities are created to identify relevant applications and potential commercial business.

The companies have already established a dialogue regarding potential areas of application. During the spring, Aurevia arranged a lunch seminar focusing on breast cancer at Uppsala University Hospital, where Lumito participated as the only invited presenting company. The seminar provided an opportunity to present the potential of the technology and establish contacts with stakeholders in a field of research where sensitive and reliable biomarker analysis is of great importance.

"The collaboration with Aurevia is an important step in our strategy to increase the commercial reach of SCIZYS. Through Aurevia's established customer relationships, we have the opportunity to reach more stakeholders who can benefit from our technology, while Aurevia can offer its customers new possibilities in advanced tissue analysis. We see significant potential in jointly identifying applications where SCIZYS can create tangible value for research and drug development," says Sanna Wallenborg, CEO of Lumito.

"We see considerable value in being able to introduce Lumito's technology to our customers in drug development and clinical research. The ability to analyse biomarkers in tissue with very high sensitivity and low background can create new possibilities for research projects where detailed and reliable tissue analysis is crucial. The collaboration gives us the opportunity, together with Lumito, to explore new applications and create added value for our customers," says Ulrika Heldestad, Business Development and Sales Director at Aurevia.

The collaboration broadens Lumito's network of CRO companies and strengthens the Company's ability to reach new customer groups. It forms part of Lumito's long-term ambition to establish SCIZYS as a valuable tool for advanced tissue analysis and contribute to the development of the precision medicine of the future.

About Aurevia AB

Aurevia is a specialised partner in clinical research and regulatory services, with a focus on the development of pharmaceuticals and medical devices. The company helps pharmaceutical, biotechnology and medical technology companies advance their products through clinical development and onwards to the market.

With a broad range of CRO services, from study design and project management to the conduct of clinical studies and regulatory support, Aurevia offers flexible solutions tailored to each customer's needs. Through expertise, close customer collaboration and international reach, Aurevia contributes to efficient development processes and high quality throughout clinical development.

About Lumito

Lumito develops and markets innovative technology that opens new possibilities for advanced tissue sample analysis in research, drug development and digital pathology.

The Company's patented SCIZYS® platform is based on upconverting nanoparticles (UCNPs), combining exceptionally high detection sensitivity with minimal background interference. This technology enables the identification and quantitative analysis of specific proteins in tissue - even at low levels that may be difficult to detect using conventional methods. The high signal stability and low background create the conditions for more detailed and reproducible tissue analysis.

SCIZYS® has the potential to contribute to the development from predominantly visual and semi-quantitative biomarker assessments towards more sensitive, objective and quantitative analysis. This can provide researchers with new tools to understand disease mechanisms, identify biomarkers and develop more individualized treatment strategies.

Lumito's vision extends beyond today's research applications. By unlocking more detailed information about biological processes, the Company aims to contribute to the development of precision medicine = where better pharmaceuticals, improved diagnostics and more informed treatment decisions can ultimately lead to enhanced patient outcomes and a more efficient use of healthcare resources.

For further information, please contact:

CEO Sanna Wallenberg
e-mail: sw@lumito.se
tel: +46 70 870 01 68

Lumito

Seeing more. Enabling precision medicine.

Towards better patient care.

www.lumito.se

The share is traded on NGM Growth Market under the ticker LUMITO.

Attachments

[Lumito strengthens its commercial position through partnership with Aurevia in advanced tissue analysis](#)